JP2012500788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500788A5 JP2012500788A5 JP2011523454A JP2011523454A JP2012500788A5 JP 2012500788 A5 JP2012500788 A5 JP 2012500788A5 JP 2011523454 A JP2011523454 A JP 2011523454A JP 2011523454 A JP2011523454 A JP 2011523454A JP 2012500788 A5 JP2012500788 A5 JP 2012500788A5
- Authority
- JP
- Japan
- Prior art keywords
- pvp
- composition according
- carrier
- taxane
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 14
- -1 sorbitan fatty acid esters Chemical class 0.000 claims 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 6
- 229940123237 Taxane Drugs 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 6
- 239000007962 solid dispersion Substances 0.000 claims 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 238000001694 spray drying Methods 0.000 claims 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 2
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims 2
- 229920003081 Povidone K 30 Polymers 0.000 claims 2
- 229920003082 Povidone K 90 Polymers 0.000 claims 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000012052 hydrophilic carrier Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920003080 Povidone K 25 Polymers 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 1
- 229960001950 benzethonium chloride Drugs 0.000 claims 1
- 229960002903 benzyl benzoate Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229960002798 cetrimide Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008387 emulsifying waxe Substances 0.000 claims 1
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000008388 non-ionic emulsifying wax Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- AHXICHPPXIGCBN-GPWPDEGDSA-N uqc681jjiv Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 AHXICHPPXIGCBN-GPWPDEGDSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBPCT/GB2008/002854 | 2008-08-22 | ||
| PCT/GB2008/002854 WO2009027644A2 (en) | 2007-08-24 | 2008-08-22 | Composition |
| PCT/GB2009/002068 WO2010020799A2 (en) | 2008-08-22 | 2009-08-24 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012500788A JP2012500788A (ja) | 2012-01-12 |
| JP2012500788A5 true JP2012500788A5 (enExample) | 2012-10-11 |
Family
ID=41229935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523454A Pending JP2012500788A (ja) | 2008-08-22 | 2009-08-24 | 組成物 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2328555A2 (enExample) |
| JP (1) | JP2012500788A (enExample) |
| WO (1) | WO2010020799A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089544B2 (en) | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| EP2525783A1 (en) * | 2010-01-18 | 2012-11-28 | Cephalon France | Improved oral lysophilisates containing pvp/va |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| CA3124319C (en) | 2018-12-21 | 2023-07-04 | Modra Pharmaceuticals B.V. | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
| PE20220250A1 (es) | 2018-12-21 | 2022-02-16 | Modra Pharmaceuticals B V | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma |
| GB202201935D0 (en) | 2022-02-14 | 2022-03-30 | Modra Pharmaceuticals B V | Methods and compositions for treating cancer in taxane-resistant patients |
| EP4385507A1 (en) | 2022-12-13 | 2024-06-19 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403634B1 (en) * | 1999-01-13 | 2002-06-11 | Aventis Pharma S.A. | Use of taxoid derivatives |
| US6610317B2 (en) * | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
| ATE312601T1 (de) * | 1999-05-27 | 2005-12-15 | Acusphere Inc | Poröse arzneistoffmatrizen und deren herstellungsverfahren |
| US20040167139A1 (en) * | 2002-07-26 | 2004-08-26 | Potter David A. | Methods of treating cancer |
| AU2003256157A1 (en) * | 2002-08-05 | 2004-02-23 | Dsm Ip Assets B.V. | Oral dosage forms of water insoluble drugs and methods of making the same |
| KR100508518B1 (ko) * | 2002-11-13 | 2005-08-17 | 한미약품 주식회사 | 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체 |
-
2009
- 2009-08-24 EP EP09785003A patent/EP2328555A2/en not_active Withdrawn
- 2009-08-24 JP JP2011523454A patent/JP2012500788A/ja active Pending
- 2009-08-24 WO PCT/GB2009/002068 patent/WO2010020799A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500788A5 (enExample) | ||
| Almeida et al. | Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): Main features and their applications in topical and transdermal administration of drugs | |
| JP5923581B2 (ja) | 局所投与に好適なイミダゾキノリン（アミン）及びその誘導体を含む医薬組成物 | |
| US11020375B2 (en) | Edaravone dosage form | |
| Cao et al. | Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs | |
| FI2346495T4 (fi) | Farmaseuttinen formulaatio 514 | |
| CN105832678A (zh) | 生物利用度提高的包含难溶性药物的微球及其制备方法 | |
| WO2011135426A1 (en) | Solid oral dosage forms comprising tadalafil | |
| JP2017523142A5 (enExample) | ||
| TW200821298A (en) | Pharmaceutical compositions | |
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| KR20160093611A (ko) | 경구 투여를 위한 약물 제제의 제조 방법 | |
| He et al. | Preparation and in vitro–in vivo evaluation of teniposide nanosuspensions | |
| JP2016503030A (ja) | 医薬組成物 | |
| JP6781717B2 (ja) | 駆虫薬の大環状ラクトンを含むミクロスフェア | |
| JP2011507838A5 (enExample) | ||
| JP2016164204A (ja) | アリピプラゾール組成物 | |
| JP2017528497A (ja) | 長時間作用型医薬組成物 | |
| EP3980023A1 (en) | Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof | |
| TWI586368B (zh) | Waterborne ophthalmic composition | |
| JP2010536837A5 (enExample) | ||
| WO2017155020A1 (ja) | 微細粒子含有組成物およびその製法 | |
| RU2488384C2 (ru) | Композиции для лечения неопластических заболеваний | |
| Long et al. | Improving the pharmacokinetics and tissue distribution of pyrinezolid by self-assembled polymeric micelles | |
| WO2015189778A1 (en) | Agomelatine in solution adsorbates and compositions |